Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Race Oncology Ltd. ( (AU:RAC) ) has provided an update.
Racura Oncology Ltd has applied to the ASX for quotation of 141,645 new fully paid ordinary shares, issued on 29 January 2026, following the exercise or conversion of existing options or other convertible securities. The additional quoted shares modestly increase the company’s free float and capital base, reflecting ongoing investor participation in Racura’s equity and potentially supporting its funding capacity for future oncology development activities.
The most recent analyst rating on (AU:RAC) stock is a Hold with a A$3.00 price target. To see the full list of analyst forecasts on Race Oncology Ltd. stock, see the AU:RAC Stock Forecast page.
More about Race Oncology Ltd.
Racura Oncology Ltd, listed on the ASX under the code RAC, operates in the oncology sector, focusing on the development of cancer-related therapies and treatments for the healthcare and biotechnology markets.
Average Trading Volume: 220,213
Technical Sentiment Signal: Buy
Current Market Cap: A$482.4M
For an in-depth examination of RAC stock, go to TipRanks’ Overview page.